Bevacizumab Concentrate for Solution for Infusion

A drug that binds to the protein VEGF to help keep new blood vessels from forming and is used to treat many different types of cancer. Bevacizumab is used under the brand names Alymsys, Mvasi, Avastin, and Zirabev, alone or with other drugs, to treat certain types of cervical cancer, colorectal cancer, non-small cell lung cancer, renal cell carcinoma (a type of kidney cancer), and glioblastoma (a type of brain cancer). The Alymsys and Avastin brands of bevacizumab are also used to treat certain types of ovarian epithelial, fallopian tube, and primary peritoneal cancer. The Avastin brand is also used to treat certain types of hepatocellular carcinoma (a type of liver cancer). Bevacizumab is also being studied in the treatment of other types of cancer. It may prevent the growth of new blood vessels that tumors need to grow. Bevacizumab is a type of antiangiogenesis agent and a type of monoclonal antibody. US Brand Name(s): Alymsys, Avastin, Mvasi, Zirabev. FDA Approved: Yes

Bevacizumab, sold under the brand name Avastin among others, is a medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).

Bevacizumab is approved to be used alone or with other drugs to treat:

Cervical cancer that has not gotten better with other treatment, has metastasized (spread to other parts of the body), or has recurred (come back). It is used with paclitaxel and either cisplatin or topotecan hydrochloride. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.

Colorectal cancer that has metastasized. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.

Hepatocellular carcinoma (a type of liver cancer) that is metastatic or cannot be removed by surgery. It is used with atezolizumab in patients who have not received systemic therapy. This use is approved for the Avastin brand of bevacizumab.

Nonsquamous non-small cell lung cancer that is locally advanced, cannot be removed by surgery, has metastasized, or has recurred. It is used with carboplatin and paclitaxel as first-line therapy. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.

Ovarian epithelial, fallopian tube, or primary peritoneal cancer.

Renal cell carcinoma (a type of kidney cancer) that has metastasized. It is used with interferon alpha. This use is approved for the Alymsys, Avastin, Mvasi, and Zirabev brands of bevacizumab.

Bevacizumab is also being studied in the treatment of other types of cancer.